ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Epigenetics >HDAC inhibitors >Entinostat

Entinostat

Entinostat Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Email: sales@capotchem.com
Products Intro: Product Name:entinostat
CAS:209783-80-2
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: Product Name:209783-80-2
CAS:209783-80-2
Purity:0.99 Package:25KG,5KG;1KG;500G
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +86 21 5161 9050/ 5187 7795
Email: ivan@atkchemical.com
Products Intro: Product Name:Entinostat
CAS:209783-80-2
Purity:98% HPLC Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: career henan chemical co
Tel: +86-371-86658258
Email: sales@coreychem.com
Products Intro: Product Name:Entinostat
CAS:209783-80-2
Purity:99% Package:1kg;2USD
Company Name: Biochempartner
Tel: 0086-13720134139
Email: candy@biochempartner.com
Products Intro: Product Name:Entinostat
CAS:209783-80-2
Purity:98% HPLC LCMS Package:10G;20G

Lastest Price from Entinostat manufacturers

  • Entinostat
  • US $2.00 / kg
  • 2019-07-06
  • CAS:209783-80-2
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
Entinostat Basic information
Product Name:Entinostat
Synonyms:CS-189;Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester;entinostat;3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]carbamate, N-(2-Aminophenyl)-4-[N-(pyridine-3ylmethoxycarbonyl)aminomethyl]benzamide;N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester;Entinostat/MS-275;Nsc706995;Entinostat(NSC-706995)
CAS:209783-80-2
MF:C21H20N4O3
MW:376.4085
EINECS:
Product Categories:SNDX 275;Entinostat;Inhibitor;API;Inhibitors
Mol File:209783-80-2.mol
Entinostat Structure
Entinostat Chemical Properties
Melting point 159-160 ºC
density 1.315
storage temp. −20°C
solubility DMSO: 38 mg/mL, soluble
form solid
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N
Safety Information
Hazard Codes Xi,T
Risk Statements 36/37/38-62-48/25-25-61
Safety Statements 26-36-45
RIDADR UN 2811 6.1 / PGIII
WGK Germany 3
HS Code 29333990
MSDS Information
Entinostat Usage And Synthesis
DescriptionEntinostat (SNDX-275, MS-275) belongs to benzamide class HDACi and inhibits HDAC1 and 2, 3 and 9 and has low effect against HDAC4, 6, 7 and 8 (Khan et al. 2007). Entinostat is in phase II clinical trial for treatment of Hodgkin's lymphoma and advanced breast cancer (in combination with aromatase inhibitors) and metastatic lung cancer (in combination with erlotinib).
Chemical PropertiesYellow Solid
UsesEntinostat is an emerging HDACi (histone deacetylase inhibitor). Entinostat is used for treatment of solid tumors and hematologic malignancies.
DefinitionChEBI: A member of the class of benzamides resulting from the formal condensation of the carboxy group of the pyridin-3-ylmethyl carbamate derivative of p-(aminomethyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an inhibit r of histone deacetylase isoform 1 (HDAC1) and isoform 3 (HDAC3).
Clinical UseEntinostat is an HDAC inhibitor with a relatively long half-life (averaging between 33 and 52 hours). Trials have shown significant biological activity in patients with hematological malignancies receiving entinostat treatments. However, the efficacy of entinostat as a single-agent therapy remains limited. Reported dose-limiting toxicities associated with entinostat include neurotoxicity, fatigue, hypophosphatemia, anorexia, and vomiting.
The large number of clinical trials using HDAC inhibitors for the treatment of patients with hematological malignancies has demonstrated that these drugs are relatively well tolerated. Although the responses with the currently-available HDAC inhibitors are still limited, there are significant responses in some patients with advanced disease, where options are limited. With better patient selection and the development of more potent HDAC inhibitors, targeting HDACs for the treatment of hematological malignancies remains promising. Furthermore, a growing body of literature suggests that HDAC inhibitors may potentiate some of the currently used cytotoxic or biologic therapies based on their mechanism of action, with multiple trials currently ongoing. Promising combination partners include proteosome inhibitors, DNA demethylating agents, and anthracyclines.
Entinostat Preparation Products And Raw materials
Tag:Entinostat(209783-80-2) Related Product Information
Everolimus Glycine PYRAZOPHOS 2-Picolinic acid 6-Aminocaproic acid Methyl POLYURETHANE Phenylacetic acid 4-Aminobenzoic acid PHENYL VALERATE Entinostat Chromium picolinate Urethane Methyl bromide CARBONYL SULFIDE 3-Aminopyridine